Duchenne Muscular Dystrophy Market

DelveInsight's "Duchenne Muscular Dystrophy - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Duchenne Muscular Dystrophy, historical and forecasted epidemiology as well as the Duchenne Muscular Dystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Duchenne Muscular Dystrophy market report provides current treatment practices, emerging drugs, Duchenne Muscular Dystrophy market share of the individual therapies, current and forecasted Duchenne Muscular Dystrophy market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Duchenne Muscular Dystrophy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.


Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Duchenne Muscular Dystrophy Disease Understanding and Treatment Algorithm

The DelveInsight Duchenne Muscular Dystrophy market report gives a thorough understanding of the Duchenne Muscular Dystrophy by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. 


Diagnosis 

This segment of the report covers the detailed diagnostic methods or tests for Duchenne Muscular Dystrophy. 


Treatment 

It covers the details of conventional and current medical therapies available in the Duchenne Muscular Dystrophy market for the treatment of the condition. It also provides Duchenne Muscular Dystrophy treatment algorithms and guidelines in the United States, Europe, and Japan. 


Duchenne Muscular Dystrophy Epidemiology  


As per the DelveInsight analysis, the total diagnosed Duchenne Muscular Dystrophy prevalent population in the 7 MM was 27,685 in 2017. 


The Duchenne Muscular Dystrophy epidemiology division provide insights about historical and current Duchenne Muscular Dystrophy patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.  


Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Duchenne Muscular Dystrophy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030. 


Country Wise- Duchenne Muscular Dystrophy Epidemiology 

The epidemiology segment also provides the Duchenne Muscular Dystrophy epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 


Duchenne Muscular Dystrophy Drug Chapters

Drug chapter segment of the Duchenne Muscular Dystrophy report encloses the detailed analysis of Duchenne Muscular Dystrophy marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Duchenne Muscular Dystrophy clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.


Marketed Drugs 

The report provides the details of the marketed product available for Duchenne Muscular Dystrophy treatment. 


Duchenne Muscular Dystrophy Emerging Drugs 

The report provides the details of the emerging therapies under the late and mid-stage of development for Duchenne Muscular Dystrophy treatment. 


Duchenne Muscular Dystrophy Market


Duchenne Muscular Dystrophy Market Outlook


"According to DelveInsight, Duchenne Muscular Dystrophy Market is Anticipated to Grow With a CAGR of 31.8% for the Study Period of 2017-2030."


The Duchenne Muscular Dystrophy market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Duchenne Muscular Dystrophy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 

This segment gives a thorough detail of Duchenne Muscular Dystrophy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 

According to DelveInsight, Duchenne Muscular Dystrophy market in 7MM is expected to change in the study period 2017-2030.


Key Findings

This section includes a glimpse of the Duchenne Muscular Dystrophy market in 7MM.


The United States Market Outlook

This section provides the total Duchenne Muscular Dystrophy market size and market size by therapies in the United States.


EU-5 Countries: Market Outlook

The total Duchenne Muscular Dystrophy market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.


Japan Market Outlook 

The total Duchenne Muscular Dystrophy market size and market size by therapies in Japan is also mentioned. 


Duchenne Muscular Dystrophy Key Companies


Duchenne Muscular Dystrophy Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Duchenne Muscular Dystrophy market or expected to get launched in the market during the study period 2017-2030. The analysis covers Duchenne Muscular Dystrophy market uptake by drugs; patient uptake by therapies; and sales of each drug.    

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Duchenne Muscular Dystrophy Pipeline Development Activities 

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Duchenne Muscular Dystrophy key players involved in developing targeted therapeutics. 


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Duchenne Muscular Dystrophy emerging therapies.


Reimbursement Scenario in Duchenne Muscular Dystrophy

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy. 


KOL- Views 

To keep up with current market trends, we take KOLs and SME's opinion working in Duchenne Muscular Dystrophy domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Duchenne Muscular Dystrophy market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs. 


Competitive Intelligence Analysis 

We perform Competitive and Market Intelligence analysis of the Duchenne Muscular Dystrophy Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.


Scope of the Report

  • The report covers the descriptive overview of Duchenne Muscular Dystrophy, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Duchenne Muscular Dystrophy epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Duchenne Muscular Dystrophy are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Duchenne Muscular Dystrophy market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Duchenne Muscular Dystrophy market


Report Highlights

  • In the coming years, Duchenne Muscular Dystrophy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Duchenne Muscular Dystrophy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition       
  • Major players are involved in developing therapies for Duchenne Muscular Dystrophy. Launch of emerging therapies will significantly impact the Duchenne Muscular Dystrophy market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Duchenne Muscular Dystrophy
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities


Duchenne Muscular Dystrophy Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Duchenne Muscular Dystrophy Pipeline Analysis
  • Duchenne Muscular Dystrophy Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies


Duchenne Muscular Dystrophy Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage 
  • Duchenne Muscular Dystrophy Epidemiology Segmentation
  • Key Cross Competition 
  • Highly Analyzed Market
  • Drugs Uptake


Duchenne Muscular Dystrophy Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers


Key Questions

Market Insights:

  • What was the Duchenne Muscular Dystrophy market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Duchenne Muscular Dystrophy total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Duchenne Muscular Dystrophy market size during the forecast period (2017-2030)?
  • At what CAGR, the Duchenne Muscular Dystrophy market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Duchenne Muscular Dystrophy market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Duchenne Muscular Dystrophy market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Duchenne Muscular Dystrophy?
  • What is the historical Duchenne Muscular Dystrophy patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Duchenne Muscular Dystrophy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Duchenne Muscular Dystrophy?
  • Out of all 7MM countries, which country would have the highest prevalent population of Duchenne Muscular Dystrophy during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Duchenne Muscular Dystrophy treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Duchenne Muscular Dystrophy in the USA, Europe, and Japan?
  • What are the Duchenne Muscular Dystrophy marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Duchenne Muscular Dystrophy?
  • How many therapies are developed by each company for Duchenne Muscular Dystrophy treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Duchenne Muscular Dystrophy treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Duchenne Muscular Dystrophy therapies? 
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies? 
  • What are the clinical studies going on for Duchenne Muscular Dystrophy and their status?
  • What are the key designations that have been granted for the emerging therapies for Duchenne Muscular Dystrophy?
  • What are the global historical and forecasted market of Duchenne Muscular Dystrophy?


Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Duchenne Muscular Dystrophy market
  • To understand the future market competition in the Duchenne Muscular Dystrophy market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Duchenne Muscular Dystrophy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Duchenne Muscular Dystrophy market
  • To understand the future market competition in the Duchenne Muscular Dystrophy market


What is Duchenne Muscular Dystrophy (DMD)?

Duchenne Muscular Dystrophy (DMD) is a progressive form of muscular dystrophy that occurs primarily in males, though in rare cases may affect females too, causing progressive weakness and loss (atrophy) of skeletal and heart muscles.


What was the Duchenne Muscular Dystrophy (DMD) market size in the major markets?

The market size of DMD in the 7 MM was found to be USD 1,011 Million in 2017, during the study period (2017-2030).


Which geography accounted for the largest Duchenne Muscular Dystrophy (DMD) market size?

The United States accounts for the largest Duchenne Muscular Dystrophy (DMD) market size in comparison to EU5 and Japan.


What are the emerging drugs for Duchenne Muscular Dystrophy (DMD)?

Emerging therapies expected to impact Duchenne Muscular Dystrophy treatment market include Casimersen, Idebenone, Edasalonexent, Talditercept alfa, Givinostat, Arbekacin, PF-06939926, Ifetroban and many others.


Which are the leading companies in Duchenne Muscular Dystrophy (DMD) market?

Companies, like Sarepta Therapeutics (Casimersen [SRP-4045]), Santhera Pharmaceuticals (Idebenone), Catabasis Pharmaceuticals(Edasalonexent), Hoffmann-La Roche (Talditercept alfa), Italfarmaco (Givinostat), Nobelpharma (Arbekacin), Pfizer (PF-06939926), Cumberland Pharma (Ifetroban) and many others are working toward the development of new treatment therapies for Duchenne Muscular Dystrophy.


How is epidemiology segmented for Duchenne Muscular Dystrophy (DMD)?

Duchenne Muscular Dystrophy Epidemiology is segmented into total prevalent cases, total diagnosed prevalent population, age-specific diagnosed prevalence, mutation-specific diagnosed prevalence and prevalent population of associated comorbidities with Duchenne Muscular Dystrophy.

1. Key Insights

2. Executive Summary of Duchenne Muscular Dystrophy

3. Competitive Intelligence Analysis for Duchenne Muscular Dystrophy

4. Duchenne Muscular Dystrophy: Market Overview at a Glance

4.1. Duchenne Muscular Dystrophy Total Market Share (%) Distribution in 2017

4.2. Duchenne Muscular Dystrophy Total Market Share (%) Distribution in 2030

5. Duchenne Muscular Dystrophy: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Risk Factors 

5.5. Diagnosis 

6. Patient Journey

7. Duchenne Muscular Dystrophy Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Duchenne Muscular Dystrophy Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Duchenne Muscular Dystrophy Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Duchenne Muscular Dystrophy Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Duchenne Muscular Dystrophy Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Duchenne Muscular Dystrophy Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Duchenne Muscular Dystrophy Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Duchenne Muscular Dystrophy Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Duchenne Muscular Dystrophy Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Duchenne Muscular Dystrophy Treatment and Management

8.2. Duchenne Muscular Dystrophy Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Duchenne Muscular Dystrophy Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Duchenne Muscular Dystrophy: Seven Major Market Analysis

13.1. Key Findings

13.2. Duchenne Muscular Dystrophy Market Size in 7MM

13.3. Duchenne Muscular Dystrophy Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Duchenne Muscular Dystrophy Total Market Size in the United States

15.1.2. Duchenne Muscular Dystrophy Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Duchenne Muscular Dystrophy Total Market Size in Germany

15.3.2. Duchenne Muscular Dystrophy Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Duchenne Muscular Dystrophy Total Market Size in France

15.4.2. Duchenne Muscular Dystrophy Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Duchenne Muscular Dystrophy Total Market Size in Italy

15.5.2. Duchenne Muscular Dystrophy Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Duchenne Muscular Dystrophy Total Market Size in Spain

15.6.2. Duchenne Muscular Dystrophy Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Duchenne Muscular Dystrophy Total Market Size in the United Kingdom

15.7.2. Duchenne Muscular Dystrophy Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Duchenne Muscular Dystrophy Total Market Size in Japan

15.8.3. Duchenne Muscular Dystrophy Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Duchenne Muscular Dystrophy

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

*The table of contents is not exhaustive; the final content may vary. 

Table 1 : 7MM Duchenne Muscular Dystrophy Epidemiology (2017-2030)

Table 2 : 7MM Duchenne Muscular Dystrophy Diagnosed and Treatable Cases (2017-2030)

Table 3 : Disease% Epidemiology in the United States (2017-2030)

Table 4 : Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in the United States (2017-2030)

Table 5 : Duchenne Muscular Dystrophy Epidemiology in Germany (2017-2030)

Table 6 : Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in Germany (2017-2030)

Table 7 : Duchenne Muscular Dystrophy Epidemiology in France (2017-2030)

Table 8 : Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in France (2017-2030) 

Table 9 : Duchenne Muscular Dystrophy Epidemiology in Italy (2017-2030)

Table 10 : Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in Italy (2017-2030)

Table 11 : Duchenne Muscular Dystrophy Epidemiology in Spain (2017-2030)

Table 12 : Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in Spain (2017-2030)

Table 13 : Duchenne Muscular Dystrophy Epidemiology in the UK (2017-2030)

Table 14 : Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in the UK (2017-2030)

Table 15 : Duchenne Muscular Dystrophy Epidemiology in Japan (2017-2030)

Table 16 : Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in Japan (2017-2030)

Table 17 : Drug Name, Clinical Trials by Recruitment status

Table 18 : Drug Name, Clinical Trials by Zone

Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)

Table 20 : Region-wise Market Size in USD, Million (2017-2030)

Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)

Table 22 : United States Market Size in USD, Million (2017-2030)

Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)

Table 24 : Germany Market Size in USD, Million (2017-2030)

Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)

Table 26 : France Market Size in USD, Million (2017-2030)

Table 27 : France Market Size by Therapy in USD, Million (2017-2030)

Table 28 : Italy Market Size in USD, Million (2017-2030)

Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)

Table 30 : Spain Market Size in USD, Million (2017-2030)

Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)

Table 32 : United Kingdom Market Size in USD, Million (2017-2030)

Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)

Table 34 : Japan Market Size in USD, Million (2017-2030)

Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

*The list of tables is not exhaustive; the final content may vary

Figure 1 : 7MM Duchenne Muscular Dystrophy Epidemiology (2017-2030)

Figure 2 : 7MM Duchenne Muscular Dystrophy Diagnosed and Treatable Cases (2017-2030)

Figure 3 : Duchenne Muscular Dystrophy Epidemiology in the United States (2017-2030)

Figure 4 : Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5 : Duchenne Muscular Dystrophy Epidemiology in Germany (2017-2030)

Figure 6 : Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7 : Duchenne Muscular Dystrophy Epidemiology in France (2017-2030)

Figure 8 : Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in France (2017-2030) 

Figure 9 : Duchenne Muscular Dystrophy Epidemiology in Italy (2017-2030)

Figure 10 : Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 : Duchenne Muscular Dystrophy Epidemiology in Spain (2017-2030)

Figure 12 : Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 : Duchenne Muscular Dystrophy Epidemiology in the UK (2017-2030)

Figure 14 : Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in the UK (2017-2030)

Figure 15 : Duchenne Muscular Dystrophy Epidemiology in Japan (2017-2030)

Figure 16 : Duchenne Muscular Dystrophy Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 17 : Drug Name, Clinical Trials by Recruitment status

Figure 18 : Drug Name, Clinical Trials by Zone

Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)

Figure 20 : Region-wise Market Size in USD, Million (2017-2030)

Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)

Figure 22 : United States Market Size in USD, Million (2017-2030)

Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)

Figure 24 : Germany Market Size in USD, Million (2017-2030)

Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)

Figure 26 : France Market Size in USD, Million (2017-2030)

Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)

Figure 28 : Italy Market Size in USD, Million (2017-2030)

Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)

Figure 30 : Spain Market Size in USD, Million (2017-2030)

Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)

Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)

Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)

Figure 34 : Japan Market Size in USD, Million (2017-2030)

Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

*The list of figures is not exhaustive; the final content may vary.

  • Sarepta Therapeutics
  • Italfarmaco
  • Catabasis Pharmaceuticals
  • Nippon Shinyaku (NS Pharma)
  • Pfizer
  • Santhera Pharmaceuticals
  • ReveraGen BioPharma
  • Taiho Pharmaceutical
  • FibroGen
  • Capricor
  • Daiichi Sankyo
  • Tags:
  • Duchenne Muscular Dystrophy market
  • Duchenne Muscular Dystrophy market...
  • Duchenne Muscular Dystrophy market...
  • Duchenne Muscular Dystrophy market...
  • Duchenne Muscular Dystrophy market...
  • Duchenne Muscular Dystrophy market...
  • Duchenne Muscular Dystrophy pipelin...
  • Duchenne Muscular Dystrophy treatme...
  • Duchenne Muscular Dystrophy drugs
  • Duchenne Muscular Dystrophy sales f...
  • Duchenne Muscular Dystrophy market...
  • Duchenne Muscular Dystrophy disease
  • Duchenne Muscular Dystrophy epidemi...
  • Duchenne Muscular Dystrophy

Forward to Friend

Need A Quote